Mark Pierce

2.8k total citations
51 papers, 2.1k citations indexed

About

Mark Pierce is a scholar working on Molecular Biology, Psychiatry and Mental health and Physiology. According to data from OpenAlex, Mark Pierce has authored 51 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 18 papers in Psychiatry and Mental health and 11 papers in Physiology. Recurrent topics in Mark Pierce's work include Migraine and Headache Studies (9 papers), Sympathectomy and Hyperhidrosis Treatments (9 papers) and Epilepsy research and treatment (8 papers). Mark Pierce is often cited by papers focused on Migraine and Headache Studies (9 papers), Sympathectomy and Hyperhidrosis Treatments (9 papers) and Epilepsy research and treatment (8 papers). Mark Pierce collaborates with scholars based in United States, United Kingdom and Denmark. Mark Pierce's co-authors include Joseph Avruch, Raphael A. Nemenoff, Martha Greiner, A. Raymond Frackelton, Hans Törnqvist, M. Amin Arnaout, Perry J. Blackshear, Rapin Osathanondh, Daniel G. Tenen and Henry T. Keutmann and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Mark Pierce

50 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Pierce United States 27 895 606 400 393 337 51 2.1k
Ethan S. Burstein United States 32 1.9k 2.2× 243 0.4× 62 0.2× 1.3k 3.3× 288 0.9× 91 3.1k
Christine A. Parker United Kingdom 24 900 1.0× 187 0.3× 82 0.2× 560 1.4× 676 2.0× 60 2.4k
Yu Nakamura Japan 30 864 1.0× 259 0.4× 62 0.2× 279 0.7× 406 1.2× 152 2.6k
Matthias Schramm Germany 26 2.0k 2.3× 186 0.3× 65 0.2× 809 2.1× 1.3k 3.8× 45 3.6k
J. N. Cumings United Kingdom 30 1.0k 1.1× 307 0.5× 147 0.4× 317 0.8× 640 1.9× 89 2.7k
Jianxiong Jiang United States 31 1.1k 1.2× 522 0.9× 216 0.5× 836 2.1× 157 0.5× 71 2.8k
Daniel Paris United States 37 1.3k 1.5× 347 0.6× 47 0.1× 522 1.3× 2.0k 5.9× 100 3.9k
Nathalie Strazielle France 28 784 0.9× 115 0.2× 687 1.7× 580 1.5× 241 0.7× 58 2.8k
Masayoshi Shibata Japan 13 396 0.4× 119 0.2× 220 0.6× 504 1.3× 884 2.6× 44 2.0k
J.M. Boeynaems Belgium 26 882 1.0× 78 0.1× 55 0.1× 231 0.6× 434 1.3× 55 2.1k

Countries citing papers authored by Mark Pierce

Since Specialization
Citations

This map shows the geographic impact of Mark Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Pierce more than expected).

Fields of papers citing papers by Mark Pierce

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Pierce. The network helps show where Mark Pierce may publish in the future.

Co-authorship network of co-authors of Mark Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Pierce. A scholar is included among the top collaborators of Mark Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Pierce. Mark Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bigal, Marcelo E., Richard B. Lipton, Lawrence C. Newman, Mark Pierce, & Stephen D. Silberstein. (2015). Sumatriptan Iontophoretic Transdermal System Reduces Treatment‐Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline – Results From a Randomized Controlled Trial. Headache The Journal of Head and Face Pain. 55(8). 1124–1132. 5 indexed citations
2.
Pierce, Mark. (2013). Oral Triptans and Nausea: Treatment Considerations in Migraine. Headache The Journal of Head and Face Pain. 53(S1). 17–20. 11 indexed citations
3.
Smith, Timothy R., et al.. (2012). Twelve‐Month Tolerability and Efficacy Study of NP101, the Sumatriptan Iontophoretic Transdermal System. Headache The Journal of Head and Face Pain. 52(4). 612–624. 26 indexed citations
4.
Pierce, Mark. (2010). Transdermal Delivery of Sumatriptan for the Treatment of Acute Migraine. Neurotherapeutics. 7(2). 159–163. 27 indexed citations
5.
Pierce, Mark, Thomas Marbury, Carol O’Neill, et al.. (2009). Zelrix™: A Novel Transdermal Formulation of Sumatriptan. Headache The Journal of Head and Face Pain. 49(6). 817–825. 49 indexed citations
6.
Pande, Atul C., et al.. (1999). Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biological Psychiatry. 46(6). 860–862. 38 indexed citations
7.
Gracon, Stephen, Margaret J. Knapp, Mark Pierce, et al.. (1998). Safety of Tacrine: Clinical Trials, Treatment IND, and Postmarketing Experience. Alzheimer Disease & Associated Disorders. 12(2). 93–101. 84 indexed citations
8.
Chadwick, David, Henning Anhut, Martha Greiner, et al.. (1998). A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology. 51(5). 1282–1288. 160 indexed citations
9.
Bergey, Gregory K., Harold H. Morris, William E. Rosenfeld, et al.. (1997). Gabapentin monotherapy: I. An 8-day, double-blind, dose controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology. 49(3). 739–745. 73 indexed citations
10.
11.
Pyke, Robert E., et al.. (1996). Analgesic Efficacy of the κ-Receptor Agonist, Enadoline, in Dental Surgery Pain. Clinical Neuropharmacology. 19(1). 92–97. 49 indexed citations
12.
Richens, A., David Chadwick, John S. Duncan, et al.. (1995). Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial. Epilepsy Research. 21(1). 37–42. 78 indexed citations
13.
Pyke, Robert E., Neal R. Cutler, Edward E. Schweizer, et al.. (1995). A Double-Blind, Placebo-Controlled Study of a CCK-B Receptor Antagonist, CI-988, in Patients With Generalized Anxiety Disorder. Journal of Clinical Psychopharmacology. 15(6). 428–434. 63 indexed citations
14.
Crowder, John E., et al.. (1991). Estazolam treatment of insomnia in generalized anxiety disorder: a placebo-controlled study.. PubMed. 11(4). 249–53. 19 indexed citations
15.
Pierce, Mark, et al.. (1990). Safety of estazolam. The American Journal of Medicine. 88(3). S12–S17. 12 indexed citations
16.
Pierce, Mark & Vincent Shu. (1990). Efficacy of estazolam:. The American Journal of Medicine. 88(3). S6–S11. 11 indexed citations
17.
Dana, N, et al.. (1987). Leukocytes from four patients with complete or partial Leu-CAM deficiency contain the common beta-subunit precursor and beta-subunit messenger RNA.. Journal of Clinical Investigation. 79(3). 1010–1015. 51 indexed citations
18.
Pierce, Mark & Clinton E. Ballou. (1983). Cell-cell recognition in yeast. Characterization of the sexual agglutination factors from Saccharomyces kluyveri.. Journal of Biological Chemistry. 258(6). 3576–3582. 45 indexed citations
19.
Keutmann, Henry T., et al.. (1983). Phosphorylation of human choriogonadotropin. Stoichiometry and sites of phosphate incorporation.. Journal of Biological Chemistry. 258(23). 14521–14526. 33 indexed citations
20.
Pierce, Mark, L. Bukowiecki, Kjell Asplund, & Norbert Freinkel. (1976). [32P] Orthophosphate Efflux from Pancreatic Islets: Graded Response to Glucose Stimulation. Hormone and Metabolic Research. 8(5). 358–361. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ethan S. Burstein Breakdown of academic impact, for papers by Christine A. Parker Breakdown of academic impact, for papers by Yu Nakamura Breakdown of academic impact, for papers by Matthias Schramm Breakdown of academic impact, for papers by J. N. Cumings Breakdown of academic impact, for papers by Jianxiong Jiang Breakdown of academic impact, for papers by Daniel Paris Breakdown of academic impact, for papers by Nathalie Strazielle Breakdown of academic impact, for papers by Masayoshi Shibata Breakdown of academic impact, for papers by J.M. Boeynaems
Rankless by CCL
2026